
The Readout
Your guide to what’s new in biotech. Sign up for the newsletter here.
Most Read


The saga of a ‘criminal’ short report, Moderna’s valuation, & UniQure’s patents

Pfizer’s 95% vaccine efficacy, disappointment in ALS, & FDA promises of transparency

More good Pfizer news, BMS underpays, & prior Covid’s one shot response

BGI’s meteoric rise, Delcath’s debatable success, & remembering John Martin

Humanigen’s narrow victory, Warp Speed lives, & relief for Uniqure

IPO anticlimax, Covid-19 vaccine questions, and a new prion approach
